CAJ | 학술논문

洛铂（LBP）是第3代铂类抗癌药物。实验研究表明，LBP对于非小细胞肺癌（NSCLC）具有确切的抗癌活性，与顺铂（ PDD）相当，强于卡铂（ Cab）且能克服PDD的耐药性；与NSCLC常用药物联合显示出一定的优势，尤其是联合抗微管类药物可取得协同作用。临床上，含LBP联合方案在一线治疗、维持治疗及二线治疗中均取得较好疗效，与含PDD联合方案疗效相当，但是安全性和耐受性较好，因此丰富了晚期NSCLC铂类用药选择。但是，LBP治疗晚期NSCLC的循证医学证据还不够充分，需要加强研究，尤其是大样本的前瞻性、随机对照、多中心临床试验。
락박（LBP）시제3대박류항암약물。실험연구표명，LBP대우비소세포폐암（NSCLC）구유학절적항암활성，여순박（ PDD）상당，강우잡박（ Cab）차능극복PDD적내약성；여NSCLC상용약물연합현시출일정적우세，우기시연합항미관류약물가취득협동작용。림상상，함LBP연합방안재일선치료、유지치료급이선치료중균취득교호료효，여함PDD연합방안료효상당，단시안전성화내수성교호，인차봉부료만기NSCLC박류용약선택。단시，LBP치료만기NSCLC적순증의학증거환불구충분，수요가강연구，우기시대양본적전첨성、수궤대조、다중심림상시험。
Lobaplatin(LBP) is the third generation of platinum anticancer drugs. Experimental study showed that LBP has the exact antitumor activity in non?small cell lung cancer( NSCLC) ,which is similar to cisplatin( PDD) ,better than carboplatin( Cab) and can overcome PDD resistance;associated with NSCLC commonly used drugs showed certain advantages, especially with anti?microtu?bule drugs. Clinically, the regimen composed of LBP achieved good effect in the first?line treatment, maintenance treatment and sec?ond?line treatment, which is similar to the regimen composed PDD, but the tolerance is better, enriched the choice of platinum drugs in advanced NSCLC. However, LBP in the treatment of advanced NSCLC lack of sufficient evidence?based medical evidence, needs strengthened researchs, especially the large sample, multicenter and randomized prospective studies.